drugset / Trial / NCT06250036
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)
Timeline
- Start
- 2025-02-20
- Primary completion
- 2027-03-20
- Completion
- 2031-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Domvanalimab | Monoclonal antibody | — | — |
| Subject | Zimberelimab | Monoclonal antibody | — | — |